Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 607K | 568K | 506K | 181K | 0 |
| Gross Profit | 481K | 343K | 388K | 129K | 0 |
| Operating Income | -9M | -12M | -6M | -3M | -2M |
| EBITDA | -9M | -11M | -5M | -3M | -2M |
| Net Income | -31M | -13M | -6M | -3M | -11M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Theralink Technologies, Inc. (THER) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +6.8%, EPS growth of -127.3%, a dividend yield of 0.0%. What stands out right now is revenue +6.8%, EPS -127.3%, free cash flow -7.6% with operating margin -1479.8% and ROIC 48.9%. Valuation is more restrained than many high-expectation growth names at price/sales 1.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines THER price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
THER
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
THER Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for THER and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$11.2M
-248.7% YoY
Free Cash Flow
-$1.2M
+70.7% YoY
Revenue Growth
+6.8%
EPS Growth
-127.3%
Gross Margin
79.2%
Net Margin
-5093.6%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 607K | 568K | 506K | 181K | 0 |
| Gross Profit | 481K | 343K | 388K | 129K | 0 |
| Operating Income | -9M | -12M | -6M | -3M | -2M |
| EBITDA | -9M | -11M | -5M | -3M | -2M |
| Net Income | -31M | -13M | -6M | -3M | -11M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 997K | 393K | 314K | 2M | 21K |
| Total Assets | 3M | 3M | 2M | 3M | 94K |
| Total Liabilities | 41M | 6M | 4M | 2M | 16M |
| Shareholder Equity | -38M | -4M | -2M | 2M | -16M |
| Total Debt | 20M | 4M | 479K | 392K | 3M |
| Net Debt | 19M | 4M | 165K | -1M | 3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+66.3% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
1M
+70.7% YoY
Key ratios
Gross Margin
79.2%
Operating Margin
-1479.8%
Net Margin
-5093.6%
ROE
147.5%
Debt / Equity
-0.52x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.